Bod meets with Linnea to progress plans to develop, manufacture and commercialise Linnea’s standardised cannabis extracts from Switzerland - Quicker importation given it is a standardised GMP manufactured extract which has the potential to be classified as a finished good - Nioskin™ base product available for immediate import - With recent regulatory changes Bod is exploring the option to apply for an import licence for a finished good in the form of a standardised oil - Approval process and the timing to market is significantly reduced with a finished good with sales to commence immediately following importation - Using a standardised specific extract is the only way medicinal cannabis can play a role in the long-term treatment of various indications
BDA Price at posting:
22.0¢ Sentiment: Buy Disclosure: Held
